Table 2 Outcomes after DAA therapy

Development of HCC

15/279

5.4% (3.3–8.7%)

 De-novo HCC occurrence

8/261

3.1% (1.6–5.9%)

 HCC recurrence

7/18

38.9% (20.3–61.4%)

Newly developed other liver-related complications

24/279

8.6% (5.8–12.5%)

Ascites

13

Hepatic encephalopathy

7

Spontaneous bacterial peritonitis

2

Hepato-renal syndrome

1

Variceal haemorrhage

4

Portal vein thrombosis

6

All-cause mortality

12/279

4.3% (2.5–7.4%)